Phase III
A Phase 3, Randomized, Multicenter, Double-Blind Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib (TAK-279) Compared to Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis
- Study HIC#:2000039738
- Last Updated:03/24/2026
Contact Us
For more information about this study, including how to volunteer, contact:
Nicole Olszewski
- Phone Number: 1-203-785-5505
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
